poisar

Stocks · News reference

Natera and Incyte Announce Clinical Collaboration for Phase II Colorectal Cancer Study

Fiscal.ai

Natera and Incyte have entered into a clinical collaboration agreement to evaluate Incyte's investigational bispecific immunotherapy, INCA33890, in a new Phase II study for patients with stage 2/3 colorectal cancer.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading